Literature DB >> 34626802

IFNγ induces JAK1/STAT1/p65 NFκB-dependent interleukin-8 expression in ovarian cancer cells, resulting in their increased migration.

Sveta Padmanabhan1, Bijaya Gaire1, Yue Zou1, Mohammad M Uddin1, Daniel DeLeon1, Ivana Vancurova2.   

Abstract

Interferon-γ (IFNγ) is a pleiotropic cytokine that has a crucial role in immune response and tumor immunity. Because of its anti-tumor effects, IFNγ has been used in cancer treatment. However, IFNγ also has tumor-promoting functions that are less well understood. Here, we show that IFNγ induces expression of the pro-inflammatory and pro-angiogenic chemokine interleukin-8 (IL-8, CXCL8) in ovarian cancer (OC) cells. The IFNγ-induced IL-8 expression is dependent on JAK1, STAT1, and p65 NFκB, and is associated with an increased occupancy of K314/315 acetylated p65 NFκB and Ser-727 phosphorylated STAT1 at the IL-8 promoter. Neutralization of IL-8 using anti-IL-8 antibody reduces IFNγ-induced migration of OC cells, and their invasion ability in 3D spheroids. Together, these findings identify IL-8 as a novel target induced by IFNγ/JAK1/STAT1/p65 NFκB signaling, and indicate that the IFNγ-induced IL-8 contributes to IFNγ pro-tumorigenic effects in ovarian cancer cells.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cell invasion; Interferon-γ; Interleukin-8; JAK1; Ovarian cancer; STAT1; p65 NFκB

Mesh:

Substances:

Year:  2021        PMID: 34626802      PMCID: PMC8639749          DOI: 10.1016/j.biocel.2021.106093

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  56 in total

1.  IL-8 and cancer prognosis on immunotherapy.

Authors:  Ziad Bakouny; Toni K Choueiri
Journal:  Nat Med       Date:  2020-05       Impact factor: 53.440

2.  Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB.

Authors:  Lin-feng Chen; Yajun Mu; Warner C Greene
Journal:  EMBO J       Date:  2002-12-02       Impact factor: 11.598

3.  Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study.

Authors:  D D Von Hoff; T R Fleming; J S Macdonald; P J Goodman; J Van Damme; T D Brown; T O'Rourke; L G Feun; M D Keppen
Journal:  J Biol Response Mod       Date:  1990-12

4.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

Review 5.  Cancer-related inflammation.

Authors:  Alberto Mantovani; Paola Allavena; Antonio Sica; Frances Balkwill
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962

6.  Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design.

Authors:  J H Schiller; M Pugh; J M Kirkwood; D Karp; M Larson; E Borden
Journal:  Clin Cancer Res       Date:  1996-01       Impact factor: 12.531

7.  Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins.

Authors:  Miguel F Sanmamed; Omar Carranza-Rua; Carlos Alfaro; Carmen Oñate; Salvador Martín-Algarra; Guiomar Perez; Sara F Landazuri; Alvaro Gonzalez; Stefanie Gross; Inmaculada Rodriguez; Cecilia Muñoz-Calleja; María Rodríguez-Ruiz; Bruno Sangro; José M López-Picazo; Manglio Rizzo; Guillermo Mazzolini; Juan I Pascual; Maria Pilar Andueza; Jose Luis Perez-Gracia; Ignacio Melero
Journal:  Clin Cancer Res       Date:  2014-09-15       Impact factor: 12.531

8.  IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.

Authors:  K Abiko; N Matsumura; J Hamanishi; N Horikawa; R Murakami; K Yamaguchi; Y Yoshioka; T Baba; I Konishi; M Mandai
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

Review 9.  The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion.

Authors:  Marija Mojic; Kazuyoshi Takeda; Yoshihiro Hayakawa
Journal:  Int J Mol Sci       Date:  2017-12-28       Impact factor: 5.923

10.  Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.

Authors:  Marijo Bilusic; Christopher R Heery; Julie M Collins; Renee N Donahue; Claudia Palena; Ravi A Madan; Fatima Karzai; Jennifer L Marté; Julius Strauss; Margaret E Gatti-Mays; Jeffrey Schlom; James L Gulley
Journal:  J Immunother Cancer       Date:  2019-09-05       Impact factor: 13.751

View more
  1 in total

Review 1.  Insulin and cancer: a tangled web.

Authors:  Brooks P Leitner; Stephan Siebel; Ngozi D Akingbesote; Xinyi Zhang; Rachel J Perry
Journal:  Biochem J       Date:  2022-03-18       Impact factor: 3.766

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.